HIV/AIDS Clinical Trial
Official title:
Effects of Acute Alcohol on Sex-Specific Delay Discounting and Subsequent Sexual Decision Making Among MSM
For decades, men who have sex with men (MSM) have carried the heaviest burden associated with
the HIV epidemic in the United States. Although MSM represent a minority (i.e., approximately
4%) of the male population in the United States, in 2010 MSM accounted for 78% of new HIV
infections among males. Furthermore, the estimated number of new HIV infections attributed to
male-to-male sexual contact is currently rising. In order to improve interventions to
decrease transmission of HIV among MSM, it is important to have a better understanding of
predictors of risky sexual behavior. Alcohol use is among the most reliable predictors of
risky sexual behavior. Unfortunately, studies of alcohol use and risky sex among MSM have
mainly relied on survey-based methods that cannot advance our understanding of the causal
mechanisms linking acute alcohol use to HIV risk behavior.
This study will utilize an "alcohol/placebo/nonalcohol" design to examine the mechanisms
underlying the association between the acute effects of alcohol (i.e., pharmacological and
expectancy) and risky sexual decision making in MSM. Focal mechanisms include sex-specific
delay discounting (SSDD), and the core constructs of the Cognitive Mediation Model. The
alcohol/placebo/nonalcohol design involves three conditions. In the alcohol condition (target
BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive
beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in
his presence. In the placebo condition (target BrAC = 0.000g%), the participant will be told
he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from
a vodka bottle) and tonic water, with a minimal amount of vodka "floated" on the surface
(using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and
mint, all mixed in his presence and served in glasses with vodka-soaked rims. In the true
control (or nonalcohol) condition, the participant will be told he is receiving no alcohol
and will be given water (poured in his presence) in a volume comparable to the other
conditions. This 3-group design will enable us to test the pharmacological effects of alcohol
while accounting for potential expectancy effects. Participants (Target N = 150-180) will be
randomly assigned to one condition; all will undergo the same protocol, which will be
completed within one experimental session. The study protocol consists of baseline
assessment, followed by beverage administration, followed by post-drinking assessment of SSDD
and sexual decision making, followed by debriefing.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | February 28, 2019 |
Est. primary completion date | February 28, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 21 Years to 35 Years |
Eligibility |
Inclusion Criteria: - single (i.e., not in a mutually monogamous relationship for at least 3 months) - sexually active as defined by any anal sex (i.e., receptive or insertive) with another man in the past 12 months - have had condomless anal sex with a male partner in their lifetime - have had at least one sexual encounter with a male partner met online in their lifetime - characterized as a current heavy drinker, as defined by self-report of one or more episodes of heavy drinking (i.e., =5 standard drinks in a single occasion) during the past 30 days; and 5) HIV negative, based on self-report. Exclusion Criteria: - Non-drinkers and light to moderate drinkers - Individuals with current alcohol problems (as indexed by an AUDIT score =16) - Individuals with current drug problems (as indexed by a DAST score =6) - Females (as this is a study of men who have sex with men). |
Country | Name | City | State |
---|---|---|---|
United States | Center for Alcohol and Addiction Studies | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Brown University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sexual Partner Delay Discounting Task | This delay discounting task measures hypothetical choice preference for immediately available sexual partners versus delayed but more attractive sexual partners. Data collected across 35 items is used to calculate a discounting rate, with a higher rate suggesting a more impulsive preference for immediate sexual activity. | Approximately 20-30 minutes after beverage administration within our single-session, lab-based protocol. | |
Primary | Sex Discounting Task | This discounting task measures the degree to which the value of hypothetical condom-protected sex decreases as a product of the amount of time one would have to wait for a condom to be available. Data collected across 32 items is used to calculate a discounting rate, with a higher rate suggesting a more impulsive preference for immediate and condomless sexual activity. | Approximately 20-30 minutes after beverage administration within our single-session, lab-based protocol. | |
Primary | Condomless Anal Sex Intentions | In the context of this laboratory-based experiment, participants read a hypothetical scenario depicting a sexual interaction with a casual sexual partner. Intention to have condomless anal sex with this partner is assessed in the middle and at the end of this scenario. Intention is rates as "yes" or "no" in response to the question "In this situation, do you have anal sex with [this partner] without a condom?" | Approximately 45-50 minutes after beverage administration within our single-session, lab-based protocol. | |
Secondary | Perceived Sex Potential | In the context of this laboratory-based experiment, participants read a hypothetical scenario depicting a sexual interaction with a casual sexual partner. Perceives sex potential is assessed at the beginning of the scenario by asking "In this scenario, how likely are you to have sex tonight?" Participants respond using an 11-point scale with "0" anchored at "not at all likely" and "10" anchored at "very likely." | Approximately 35 minutes after beverage administration within our single-session, lab-based protocol. | |
Secondary | Perceived Sexual Risks and Benefits Scale | In the context of this laboratory-based experiment, participants read a hypothetical scenario depicting a sexual interaction with a casual sexual partner. Within the scenario, participants are asked "When thinking about whether or not to have sex with this partner tonight, would you consider each of the following reasons? Please mark YES if you would consider the reason, and NO if you would not consider it in this situation." The list comprises 34 items, including 17 perceived risks and 17 perceived benefits. For each risk and benefit endorsed, participants also rate the extent to which the reason would influence their decision using a 5-point scale, with "0" anchored at "not influential and "5" anchored at "extremely influential." | Approximately 40 minutes after beverage administration within our single-session, lab-based protocol. | |
Secondary | Online Sexual Communication | In the context of this laboratory-based experiment, participants read a hypothetical scenario depicting a sexual interaction with a casual sexual partner. During the scenario, the participant is asked "At this point in the story, would you want to talk about anything else before agreeing to meet?" Participants who answer"yes" are then asked "What else you would want to talk about? Please use the text boxes below to describe what else you want to talk about." Responses are open ended. Finally, participants are asked "Each of the topics you want to discuss with this partner are listed below. For each, please write down exactly how you would ask this partner on Grindr. If you would use emoji in your message, please describe which ones?" Again, responses are open ended. These data are qualitative in nature. | Approximately 45 minutes after beverage administration within our single-session, lab-based protocol. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|